Dulaglutide

Dulaglutide is a long-acting GLP-1 receptor agonist built on an IgG4-Fc fusion protein platform. It was FDA-approved on September 18, 2014 for the treatment of type 2 diabetes mellitus, and on February 21, 2020 for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have or do not have established cardiovascular disease. The drug is administered once weekly by subcutaneous injection at doses of 0.75 mg, 1.5 mg, 3 mg, or 4.5 mg.

Dulaglutide is an engineered peptide with approximately 90 percent amino acid sequence homology to native human GLP-1 (7-37), fused to a modified human IgG4-Fc domain via a small flexible linker. The Fc fusion serves two purposes: it extends the half-life to approximately 5 days by binding the neonatal Fc receptor (FcRn), and it increases the molecular weight enough to reduce renal clearance. The molecule resists dipeptidyl peptidase-4 (DPP-4) degradation, which destroys native GLP-1 within minutes. The resulting pharmacokinetic profile supports steady-state once-weekly dosing without need for titration.

The AWARD Program

Eli Lilly's Phase 3 development program for dulaglutide was the AWARD program (Assessment of Weekly AdministRation of LY2189265 in Diabetes). Eleven AWARD trials studied dulaglutide as monotherapy, in combination with metformin, sulfonylureas, thiazolidinediones, basal insulin, and prandial insulin. Comparators included placebo, metformin, sitagliptin, exenatide, liraglutide, glargine, and semaglutide.

Key results across the program:

• HbA1c reduction: approximately 1.0 to 1.6 percentage points at 1.5 mg, with greater reductions at higher doses
• Body weight: approximately 2 to 4 kg loss at 1.5 mg, 4 to 5 kg at 4.5 mg over 12 months
• Low hypoglycemia risk outside of combination with insulin or sulfonylureas
• Most common adverse events: gastrointestinal (nausea, diarrhea, vomiting), typically transient and dose-related

AWARD-11 was the key trial supporting label expansion to 3 mg and 4.5 mg doses. Adults with inadequately controlled T2D on metformin who had previously been on dulaglutide 1.5 mg were randomized to continue at 1.5 mg or escalate to 3 mg or 4.5 mg. The higher doses produced greater HbA1c reduction and greater weight loss without new safety signals.

REWIND and the Cardiovascular Indication

The REWIND trial (Gerstein et al., The Lancet 2019) was the dedicated cardiovascular outcomes trial. Design: 9,901 adults with type 2 diabetes (HbA1c ≤ 9.5%), aged ≥50, randomized 1:1 to dulaglutide 1.5 mg weekly or placebo. Mean follow-up was 5.4 years, the longest in the GLP-1 receptor agonist cardiovascular outcomes trial program at the time.

Primary outcome: composite of first occurrence of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes. Result: hazard ratio 0.88 (95% CI 0.79-0.99, p=0.026), a 12 percent reduction versus placebo.

The trial was important not just for the primary outcome but for the population. Approximately 69 percent of patients did not have established cardiovascular disease at baseline. This made dulaglutide the first type 2 diabetes drug to demonstrate cardiovascular event reduction in a primary-prevention population. The FDA approval in February 2020 reflected this distinction.

Market Position

Dulaglutide became the most-prescribed GLP-1 receptor agonist by volume in the years following 2014. Once-weekly dosing, an autoinjector that does not require reconstitution or dose dialing, and no titration requirement made it the most patient-friendly option in the class for the second half of the 2010s. Peak annual sales exceeded $7 billion.

Market position has been displaced by semaglutide (Ozempic for T2D, Wegovy for obesity) and tirzepatide (Mounjaro for T2D, Zepbound for obesity). Both produce greater weight loss in head-to-head trials. Semaglutide's SUSTAIN-7 trial directly compared semaglutide and dulaglutide and showed superior HbA1c reduction and weight loss for semaglutide. Tirzepatide trials similarly outperformed dulaglutide.

A Chinese biosimilar (LY05008) completed a Phase 3 head-to-head trial against dulaglutide in 2025 with comparable efficacy and safety. US patent expiry is anticipated in the late 2020s, after which biosimilar competition is expected to materially affect pricing.

Dulaglutide binds and activates the GLP-1 receptor, a G protein-coupled receptor expressed on pancreatic beta cells, alpha cells, central nervous system neurons (particularly in hypothalamic and brainstem feeding circuits), and gastrointestinal cells. The molecule mimics the action of native GLP-1, an incretin hormone secreted by intestinal L cells in response to food intake.

Receptor activation triggers Gs-coupled adenylyl cyclase signaling, raising intracellular cyclic AMP. The downstream effects:

• Glucose-dependent insulin secretion: dulaglutide stimulates insulin release only when blood glucose is elevated. This dependency on hyperglycemia is what gives the class its low risk of hypoglycemia in monotherapy.
• Glucagon suppression: alpha-cell glucagon secretion decreases, reducing hepatic glucose output.
• Delayed gastric emptying: slowing gastric emptying reduces postprandial glucose excursions and increases satiety.
• Central appetite suppression: GLP-1 receptors in the arcuate nucleus, nucleus tractus solitarius, and area postrema reduce food intake and increase satiety signaling.
• Beta-cell preservation: preclinical data suggests GLP-1 receptor agonism may slow beta-cell decline, though human evidence is mixed.

The cardiovascular benefit mechanism is incompletely understood. Proposed contributors include improved endothelial function, modest blood pressure reduction (1-2 mmHg systolic), favorable changes in lipids, anti-inflammatory effects on vascular tissue, and direct cardioprotective effects unrelated to glycemic control. The REWIND benefit was apparent across glycemic strata, suggesting non-glycemic mechanisms contribute.

Dulaglutide's specific molecular advantages over earlier GLP-1 receptor agonists are kinetic, not mechanistic. The IgG4-Fc fusion extends half-life enough to support once-weekly dosing at flat plasma concentrations, reducing the peak-trough variability seen with shorter-acting agents like exenatide twice daily.

Glycemic effects (AWARD program at 1.5 mg dose, 26-52 weeks):

• HbA1c reduction approximately 1.0 to 1.6 percentage points
• Fasting plasma glucose reduction approximately 30 to 45 mg/dL
• Postprandial glucose reduction comparable

Glycemic effects at higher doses (AWARD-11):

• 3 mg: additional HbA1c reduction of approximately 0.2 percentage points versus 1.5 mg
• 4.5 mg: additional HbA1c reduction of approximately 0.4 percentage points versus 1.5 mg

Weight effects in diabetic populations:

• 0.75 mg: approximately 1.5 to 2 kg over 6-12 months
• 1.5 mg: approximately 2 to 4 kg over 12 months
• 3 mg: approximately 3 to 5 kg over 12 months
• 4.5 mg: approximately 4 to 5 kg over 12 months

Cardiovascular effects (REWIND):

• 12 percent reduction in MACE (composite of nonfatal MI, nonfatal stroke, CV death)
• Reduced microvascular composite outcome (renal and retinal endpoints)
• No effect on hospitalization for heart failure
• No effect on all-cause mortality individually

Renal effects: dulaglutide reduced a composite renal outcome (new macroalbuminuria, sustained 30% decline in eGFR, or end-stage renal disease) by approximately 15 percent in REWIND, with the effect driven primarily by reduced macroalbuminuria.

Reported patient experience in real-world use:

• Nausea is the most common adverse effect, typically present for the first 2-4 weeks of treatment and resolving without intervention
• Reduced appetite, smaller portion sizes, and earlier satiety are commonly reported
• Some patients report aversion to specific foods (particularly high-fat foods)
• Energy levels and concentration are typically unaffected at standard doses

FDA-approved dosing protocol:

• Starting dose: 0.75 mg subcutaneously once weekly
• Standard maintenance dose: 1.5 mg once weekly
• Higher doses: 3 mg and 4.5 mg once weekly for inadequate response at 1.5 mg

Dose escalation from 0.75 mg to 1.5 mg is recommended after 4 weeks if needed. From 1.5 mg to 3 mg requires another 4 weeks at the lower dose. From 3 mg to 4.5 mg requires another 4 weeks. The stepwise approach reduces gastrointestinal adverse effects.

Injection sites: abdomen, thigh, or upper arm. Sites can be rotated. The autoinjector is single-use and disposable. No refrigeration is required during the day of use, but storage is refrigerated (2-8°C) for unused pens.

Missed dose: if a dose is missed by less than 3 days, administer as soon as possible. If more than 3 days, skip the dose and resume the regular weekly schedule.

Renal impairment: no dose adjustment is required for renal impairment. Dulaglutide has been studied in patients with stage 3-4 chronic kidney disease without dose modification.

Hepatic impairment: limited data, but no dose adjustment is generally recommended.

Pediatric population: dulaglutide has been studied in adolescents aged 10-17 with type 2 diabetes (AWARD-PEDS trial) and is approved for this population at the 0.75 mg dose.

Off-label use for weight loss in non-diabetic patients: not FDA-approved. Some clinicians prescribe dulaglutide off-label for obesity, though the regulatory pathway for non-diabetic weight management is semaglutide (Wegovy) or tirzepatide (Zepbound), both of which have dedicated obesity indications. Insurance coverage for dulaglutide in non-diabetic patients is typically not available.

Common adverse effects (≥5% incidence):

• Nausea (12-21% depending on dose, vs 5% placebo)
• Diarrhea (8-13%)
• Vomiting (6-13%)
• Abdominal pain (6-9%)
• Decreased appetite (5-9%)
• Fatigue (4-6%)
• Injection site reactions (mild redness or itching)

GI effects are typically dose-related, more common with dose escalation, and resolve within 2-4 weeks for most patients.

Serious adverse effects (rare but important):

• Pancreatitis: acute pancreatitis has been reported in postmarketing surveillance. Causal relationship to dulaglutide is unconfirmed but the class label warns of this risk. Patients should discontinue if pancreatitis is suspected.
• Acute renal failure: postmarketing reports, sometimes requiring hemodialysis, usually associated with severe GI symptoms and resulting dehydration.
• Hypersensitivity: anaphylaxis and angioedema have been reported, more commonly with other GLP-1 receptor agonists; caution if prior reaction to any GLP-1 receptor agonist.
• Severe gastrointestinal disease: ileus has been reported.
• Diabetic retinopathy: rapid improvement in glycemic control can transiently worsen retinopathy in patients with pre-existing diabetic eye disease.

Boxed warning: thyroid C-cell tumors in rats at all clinically relevant doses with lifetime exposure. Human relevance is unknown. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) and in patients with MEN 2 syndrome.

Hypoglycemia risk is low with dulaglutide monotherapy because the insulin-secretion effect is glucose-dependent. However, combination with insulin or sulfonylureas substantially increases hypoglycemia risk and may require reduction of those concomitant medications.

Special populations:

• Pregnancy: limited data. Animal studies show developmental adverse effects at high doses. The 2023 ADA guidelines do not recommend GLP-1 receptor agonists in pregnancy. Discontinue before planned pregnancy.
• Breastfeeding: limited data. Likely transferred to milk in small amounts.
• Elderly: no dose adjustment, but increased monitoring for GI dehydration and renal function in patients >75.

Dulaglutide sits within a crowded GLP-1 receptor agonist class. The closest comparators are other once-weekly injectable GLP-1 receptor agonists:

• Semaglutide (Ozempic, Wegovy, Rybelsus): the dominant GLP-1 receptor agonist in the second half of the 2020s. Superior weight loss versus dulaglutide in SUSTAIN-7. Available as injectable (Ozempic/Wegovy) and oral tablet (Rybelsus). Has dedicated obesity indication (Wegovy) and cardiovascular outcomes data (SUSTAIN-6).
• Tirzepatide (Mounjaro, Zepbound): dual GIP/GLP-1 receptor agonist. Superior weight loss and glycemic control versus dulaglutide in SURPASS-2 (vs semaglutide) and SURPASS head-to-head trial program.
• Liraglutide (Victoza, Saxenda): once-daily injection, predecessor to dulaglutide. Lower convenience, similar mechanism. Saxenda has obesity indication.
• Retatrutide: triple GLP-1/GIP/glucagon agonist, in Phase 3 development. If approved, likely to surpass tirzepatide on weight loss.

Switching considerations: patients can switch from one GLP-1 receptor agonist to another with appropriate transition. There is no required washout period because the mechanism is identical, though dose equivalence is approximate.

Combination with insulin: dulaglutide is FDA-approved as add-on to basal insulin and to prandial insulin. The combination reduces overall insulin requirement and tends to improve weight outcomes compared to insulin alone.

Combination with SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin): a complementary combination with non-overlapping mechanisms. Both classes have independent cardiovascular and renal benefit. Combination is commonly used in patients with T2D plus established CVD or CKD.

Combination with metformin: standard. Most AWARD trials studied this combination.

Combinations to avoid or use with caution:

• Insulin secretagogues (sulfonylureas, meglitinides): increased hypoglycemia risk. Dose reduction of the secretagogue is appropriate when starting dulaglutide.
• DPP-4 inhibitors (sitagliptin, linagliptin, etc.): mechanistically redundant. Both classes target the incretin system. There is no benefit to combining them.
• Off-label combinations with non-GLP-1 weight-loss compounds (Tesofensine, 5-Amino-1MQ, SLU-PP-332): not studied in any controlled trial. Combined cardiovascular and GI burden is not characterized.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.